Metabolism, Diabetes, and Cancer / Adipokines, Inflammation, and Metabolic Diseases · Journal article

Kaempferol CounteractsObesity and Impairs Adipogenesisby Suppressing PI3K/AKT/GSK3β-Mediated Mitotic Clonal Expansionand Attenuating Adipose Tissue Fibrosis

Journal of Agricultural and Food Chemistry · August 10, 2026

Hypothesis-Generating Why this matters to you Expert discussion

Raises a question worth testing. It does not answer one.

AI Summary

This is a mechanistic investigation of kaempferol's effects on adipocyte differentiation in vitro and obesity phenotype in a high-fat diet mouse model. The study identifies inhibition of the PI3K/AKT/GSK3β pathway as a putative mechanism and shows reduction in body weight gain and adipose tissue fibrosis in mice, but provides no human evidence and lacks quantified effect sizes for the reported outcomes.

What was studied

In vitro (cell culture) and in vivo (diet-induced obesity mouse model) mechanistic study. 3T3-L1 mouse preadipocyte cell line and high-fat diet-fed mice; no human subjects. Intervention: Kaempferol (dietary flavonoid). Compared with: Control (untreated preadipocytes and standard diet or vehicle-treated obese mice); AKT activator SC79 used as mechanistic probe.

Key findings

Kaempferol inhibited preadipocyte differentiation at S-phase (18 h) and G2/M-phase (24 h) via cell cycle arrest in 3T3-L1 cells AKT activator SC79 confirmed kaempferol suppresses AKT phosphorylation to inhibit terminal adipogenesis In vivo, kaempferol significantly alleviated HFD-induced body weight gain, adiposity, dyslipidemia, and insulin resistance in mice

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

This work suggests a biological mechanism by which kaempferol may modulate obesity risk, but evidence is limited to cell and animal models. Human trials with hard clinical outcomes (weight loss, metabolic parameters, cardiovascular or mortality benefits) are required before kaempferol can be recommended as a therapeutic intervention for obesity.

Plain-language summary

Mechanistic study in cell culture and diet-induced obesity model with surrogate endpoints; establishes a biological pathway but lacks human evidence and hard clinical outcomes needed to guide practice.

Study design

As stated by the source record.

MethodsKaempferol was applied to 3T3-L1 preadipocytes and cell cycle arrest was assessed at S-phase (18 h) and G2/M-phase (24 h). An AKT activator (SC79) was used to confirm suppression of the PI3K/AKT/GSK3β pathway. In vivo, mice were fed a high-fat diet and treated with kaempferol; body composition, lipid profiles, insulin sensitivity, gene expression, and adipose tissue histology were analysed.

DesignIn vitro (cell culture) and in vivo (diet-induced obesity mouse model) mechanistic study

Population3T3-L1 mouse preadipocyte cell line and high-fat diet-fed mice; no human subjects

InterventionKaempferol (dietary flavonoid)

ComparatorControl (untreated preadipocytes and standard diet or vehicle-treated obese mice); AKT activator SC79 used as mechanistic probe

Clinical bottom line

Caveats

No sample sizes reported for cell culture or animal experiments
No quantified effect sizes, confidence intervals, or p-values for in vivo outcomes (body weight gain, adiposity, dyslipidemia, insulin resistance)
No human data; findings are from cell culture and mice only
Mechanism is pathway-based; clinical relevance to human obesity pathogenesis is unproven

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Cell culture and animal model; no randomization, blinding, or human subjects.

Directness

limited

Surrogate endpoints (cell cycle arrest, pathway inhibition) and animal obesity model; no human efficacy or safety data.

Consistency

insufficient

Single study; no comparison to existing literature or prior human trials cited.

Risk of bias

insufficient

No description of blinding, randomization allocation, or outcome assessment independence in animal work.

Sample adequacy

insufficient

Text does not report sample size (n) for 3T3-L1 experiments or mouse cohort.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Abstract Kaempferol, a widely present dietary flavonoid in numerous fruits and vegetables, possesses antiobesity potential with unclearly defined mechanisms. This study investigated how kaempferol regulates adipogenesis in 3T3-L1 preadipocytes and exerts antiobesity effects in high-fat diet (HFD)-induced obese mice. Kaempferol inhibited preadipocyte differentiation at the early mitotic clonal expansion (MCE) stage by S-phase (18 h) and G2/M-phase (24 h) cell cycle arrest. Mechanistically, this action was mediated through inhibition of the PI3K/AKT/GSK3β pathway. Application of the AKT activator SC79 confirmed that kaempferol suppresses AKT phosphorylation to inhibit terminal adipogenesis. In vivo, kaempferol significantly alleviated HFD-induced body weight gain, adiposity, dyslipidemia, and insulin resistance. Transcriptomic and histological analyses revealed that kaempferol reversed obesity-associated upregulation of cell cycle and metabolic pathways in white adipose tissue and alleviated adipose tissue fibrosis. These findings underscore the potential of kaempferol as a promising functional food ingredient for preventing obesity and related metabolic diseases.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Jingsa ZhangYilu ShouMetabolism, Diabetes, and CancerXingya WangYaling TangAdipokines, Inflammation, and Metabolic DiseasesHe PengXia Du